Olema Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Olema Pharmaceuticals, Inc. filed a Form 8-K dated February 28, 2022, under Item 2.02 to report financial results for the year ended December 31, 2021. The filing identifies the company as a Delaware corporation headquartered in San Francisco, California, with common stock traded on Nasdaq under the symbol OLMA.
Financial Results and Liquidity
The filing states that the company reported its 2021 financial results, but the filing text provided does not include the underlying revenue, net income or loss, cash flow, margin, debt, cash balance, liquidity, or other financial figures. Those details were included in Exhibit 99.1, a press release dated February 28, 2022, which is referenced but not provided in the source text.
Material Changes Versus the Prior Comparable Period
The provided filing text does not disclose specific year-over-year changes or comparative financial data.
Guidance, Outlook, Risks, and Unusual Items
The provided text does not include management guidance, outlook commentary, risk updates, contingencies, or unusual items. The filing solely furnishes the company’s results press release under Item 2.02 and lists the related exhibit.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for 2021 revenue, operating expenses, net loss, cash flow, cash and equivalents, debt, and liquidity.
- Verify comparative 2020 results and the principal drivers of year-over-year changes.
- Review management’s 2022 cash runway, development plans, expected expenditures, and any forward-looking guidance.
- Check for risk factors, financing activities, clinical or regulatory developments, and other material events discussed in the press release.